Federal and state action needed to end the infectious complications of illicit drug use in the United States: IDSA and HIVMA's advocacy agenda

doi:10.1093/infdis/jiz673

Federal and state action needed to end the infectious complications of illicit drug use in the United States: IDSA and HIVMA's advocacy agenda

Research output: Contribution to journal › Article › peer-review

7 Scopus citations

Abstract

In response to the opioid crisis, IDSA and HIVMA established a working group to drive an evidence- and human rights-based response to illicit drug use and associated infectious diseases. Infectious diseases and HIV physicians have an opportunity to intervene, addressing both conditions. IDSA and HIVMA have developed a policy agenda highlighting evidence-based practices that need further dissemination. This paper reviews (1) programs most relevant to infectious diseases in the 2018 SUPPORT Act; (2) opportunities offered by the “End the HIV Epidemic” initiative; and (3) policy changes necessary to affect the trajectory of the opioid epidemic and associated infections. Issues addressed include leveraging harm reduction tools and improving integrated prevention and treatment services for the infectious diseases and substance use disorder care continuum. By strengthening collaborations between infectious diseases and addiction specialists, including increasing training in substance use disorder treatment among infectious diseases and addiction specialists, we can decrease morbidity and mortality associated with these overlapping epidemics.

Original language	English
Pages (from-to)	S230-S238
Journal	Journal of Infectious Diseases
Volume	222
Issue number	Supplement_5
DOIs	https://doi.org/10.1093/infdis/jiz673
State	Published - Oct 1 2020

Bibliographical note

Funding Information:
This work was supported by the National Institute on Drug Abuse, National Institutes of Health (grant number K02 DA032322 for career development to S. A. S.).

Publisher Copyright:
© The Author(s) 2020. Published by Oxford University Press for the Infectious Diseases Society of America. This is an Open Access article distributed under the terms of the Creative Commons Attribution-NonCommercial-NoDerivs licence (http://creativecommons.org/licenses/ by-nc-nd/4.0/), which permits non-commercial reproduction and distribution of the work, in any medium, provided the original work is not altered or transformed in any way, and that the work is properly cited.

Keywords

Injection drug use
Medications for treatment of opioid use disorder
Opioid epidemic

ASJC Scopus subject areas

Immunology and Allergy
Infectious Diseases

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Access to Document

10.1093/infdis/jiz673

Cite this

@article{820d6cc4a51d4ac89692859f06669970,

title = "Federal and state action needed to end the infectious complications of illicit drug use in the United States: IDSA and HIVMA's advocacy agenda",

abstract = "In response to the opioid crisis, IDSA and HIVMA established a working group to drive an evidence- and human rights-based response to illicit drug use and associated infectious diseases. Infectious diseases and HIV physicians have an opportunity to intervene, addressing both conditions. IDSA and HIVMA have developed a policy agenda highlighting evidence-based practices that need further dissemination. This paper reviews (1) programs most relevant to infectious diseases in the 2018 SUPPORT Act; (2) opportunities offered by the “End the HIV Epidemic” initiative; and (3) policy changes necessary to affect the trajectory of the opioid epidemic and associated infections. Issues addressed include leveraging harm reduction tools and improving integrated prevention and treatment services for the infectious diseases and substance use disorder care continuum. By strengthening collaborations between infectious diseases and addiction specialists, including increasing training in substance use disorder treatment among infectious diseases and addiction specialists, we can decrease morbidity and mortality associated with these overlapping epidemics.",

keywords = "Injection drug use, Medications for treatment of opioid use disorder, Opioid epidemic",

author = "Springer, {Sandra A.} and Barocas, {Joshua A.} and Alysse Wurcel and Ank Nijhawan and Kinna Thakarar and Ruth Lynfield and Hermione Hurley and Jessica Snowden and Alice Thornton and {del Rio}, Carlos",

note = "Funding Information: This work was supported by the National Institute on Drug Abuse, National Institutes of Health (grant number K02 DA032322 for career development to S. A. S.). Publisher Copyright: {\textcopyright} The Author(s) 2020. Published by Oxford University Press for the Infectious Diseases Society of America. This is an Open Access article distributed under the terms of the Creative Commons Attribution-NonCommercial-NoDerivs licence (http://creativecommons.org/licenses/ by-nc-nd/4.0/), which permits non-commercial reproduction and distribution of the work, in any medium, provided the original work is not altered or transformed in any way, and that the work is properly cited.",

year = "2020",

month = oct,

day = "1",

doi = "10.1093/infdis/jiz673",

language = "English",

volume = "222",

pages = "S230--S238",

number = "Supplement_5",

}

TY - JOUR

T1 - Federal and state action needed to end the infectious complications of illicit drug use in the United States

T2 - IDSA and HIVMA's advocacy agenda

AU - Springer, Sandra A.

AU - Barocas, Joshua A.

AU - Wurcel, Alysse

AU - Nijhawan, Ank

AU - Thakarar, Kinna

AU - Lynfield, Ruth

AU - Hurley, Hermione

AU - Snowden, Jessica

AU - Thornton, Alice

AU - del Rio, Carlos

N1 - Funding Information: This work was supported by the National Institute on Drug Abuse, National Institutes of Health (grant number K02 DA032322 for career development to S. A. S.). Publisher Copyright: © The Author(s) 2020. Published by Oxford University Press for the Infectious Diseases Society of America. This is an Open Access article distributed under the terms of the Creative Commons Attribution-NonCommercial-NoDerivs licence (http://creativecommons.org/licenses/ by-nc-nd/4.0/), which permits non-commercial reproduction and distribution of the work, in any medium, provided the original work is not altered or transformed in any way, and that the work is properly cited.

PY - 2020/10/1

Y1 - 2020/10/1

N2 - In response to the opioid crisis, IDSA and HIVMA established a working group to drive an evidence- and human rights-based response to illicit drug use and associated infectious diseases. Infectious diseases and HIV physicians have an opportunity to intervene, addressing both conditions. IDSA and HIVMA have developed a policy agenda highlighting evidence-based practices that need further dissemination. This paper reviews (1) programs most relevant to infectious diseases in the 2018 SUPPORT Act; (2) opportunities offered by the “End the HIV Epidemic” initiative; and (3) policy changes necessary to affect the trajectory of the opioid epidemic and associated infections. Issues addressed include leveraging harm reduction tools and improving integrated prevention and treatment services for the infectious diseases and substance use disorder care continuum. By strengthening collaborations between infectious diseases and addiction specialists, including increasing training in substance use disorder treatment among infectious diseases and addiction specialists, we can decrease morbidity and mortality associated with these overlapping epidemics.

AB - In response to the opioid crisis, IDSA and HIVMA established a working group to drive an evidence- and human rights-based response to illicit drug use and associated infectious diseases. Infectious diseases and HIV physicians have an opportunity to intervene, addressing both conditions. IDSA and HIVMA have developed a policy agenda highlighting evidence-based practices that need further dissemination. This paper reviews (1) programs most relevant to infectious diseases in the 2018 SUPPORT Act; (2) opportunities offered by the “End the HIV Epidemic” initiative; and (3) policy changes necessary to affect the trajectory of the opioid epidemic and associated infections. Issues addressed include leveraging harm reduction tools and improving integrated prevention and treatment services for the infectious diseases and substance use disorder care continuum. By strengthening collaborations between infectious diseases and addiction specialists, including increasing training in substance use disorder treatment among infectious diseases and addiction specialists, we can decrease morbidity and mortality associated with these overlapping epidemics.

KW - Injection drug use

KW - Medications for treatment of opioid use disorder

KW - Opioid epidemic

UR - http://www.scopus.com/inward/record.url?scp=85090260946&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85090260946&partnerID=8YFLogxK

U2 - 10.1093/infdis/jiz673

DO - 10.1093/infdis/jiz673

M3 - Article

C2 - 32877568

AN - SCOPUS:85090260946

VL - 222

SP - S230-S238

IS - Supplement_5

ER -

Federal and state action needed to end the infectious complications of illicit drug use in the United States: IDSA and HIVMA's advocacy agenda

Abstract

Bibliographical note

Keywords

ASJC Scopus subject areas

UN SDGs

Access to Document

Other files and links

Fingerprint

Cite this